Wall Street brokerages expect Champions Oncology Inc (NASDAQ:CSBR) to report earnings per share of ($0.02) for the current quarter, Zacks reports. Two analysts have provided estimates for Champions Oncology’s earnings. Champions Oncology reported earnings per share of $0.03 in the same quarter last year, which suggests a negative year-over-year growth rate of 166.7%. The firm is expected to issue its next quarterly earnings report on Monday, December 16th.
According to Zacks, analysts expect that Champions Oncology will report full-year earnings of $0.01 per share for the current fiscal year. For the next year, analysts forecast that the business will post earnings of $0.20 per share. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Champions Oncology.
Champions Oncology (NASDAQ:CSBR) last announced its quarterly earnings results on Monday, September 16th. The biotechnology company reported ($0.06) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.09). The firm had revenue of $6.74 million for the quarter, compared to analysts’ expectations of $7.50 million. Champions Oncology had a negative net margin of 3.61% and a negative return on equity of 48.07%.
Several large investors have recently made changes to their positions in CSBR. Marshall Wace LLP purchased a new position in shares of Champions Oncology in the first quarter worth about $99,000. Wedge Capital Management L L P NC purchased a new position in shares of Champions Oncology in the second quarter worth about $277,000. Wells Fargo & Company MN raised its stake in shares of Champions Oncology by 110.4% in the second quarter. Wells Fargo & Company MN now owns 149,100 shares of the biotechnology company’s stock worth $1,167,000 after purchasing an additional 78,250 shares during the last quarter. Alambic Investment Management L.P. raised its stake in shares of Champions Oncology by 27.0% in the second quarter. Alambic Investment Management L.P. now owns 68,681 shares of the biotechnology company’s stock worth $538,000 after purchasing an additional 14,614 shares during the last quarter. Finally, BlackRock Inc. raised its stake in shares of Champions Oncology by 12.0% in the second quarter. BlackRock Inc. now owns 137,027 shares of the biotechnology company’s stock worth $1,073,000 after purchasing an additional 14,733 shares during the last quarter. Hedge funds and other institutional investors own 51.62% of the company’s stock.
Shares of Champions Oncology stock traded down $0.04 during trading on Tuesday, hitting $5.26. 27,400 shares of the stock traded hands, compared to its average volume of 41,816. The company has a current ratio of 0.80, a quick ratio of 0.80 and a debt-to-equity ratio of 2.06. The firm has a market cap of $61.00 million, a P/E ratio of 526.00 and a beta of 1.15. The stock’s fifty day simple moving average is $5.72 and its 200 day simple moving average is $7.15. Champions Oncology has a 52-week low of $5.01 and a 52-week high of $14.04.
About Champions Oncology
Champions Oncology, Inc develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice.
Further Reading: How to Trade Using Analysts Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Champions Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology and related companies with MarketBeat.com's FREE daily email newsletter.